Avalo Therapeutics (AVTX) Non-Current Assets (2014 - 2026)
Avalo Therapeutics posted quarterly Non-Current Assets of $11.1 million for Q1 2026, down 4.51% year-on-year from $11.6 million in Q1 2025, and down 1.0% on a QoQ basis from $11.2 million in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Non-Current Assets data on file, last reported at $11.1 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 4.51% year-over-year to $11.1 million; the trailing twelve-month figure through Mar 2026 stood at $44.9 million (down 6.77% YoY), and the FY2025 full-year result was $11.2 million, down 5.66% from the prior year.
- Non-Current Assets for Q1 2026 stood at $11.1 million, down from $11.2 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $18.2 million in Q1 2022 and bottomed at $11.1 million in Q1 2026.
- The 5-year median for Non-Current Assets is $12.5 million (2024), against an average of $14.0 million.
- The widest annual swing landed in 2022, when Non-Current Assets grew 5.75%; it then decreased 26.3% in 2024.
- A 5-year view of Non-Current Assets shows it stood at $17.0 million in 2022, then slipped by 25.68% to $12.6 million in 2023, then retreated by 6.0% to $11.8 million in 2024, then dropped by 5.66% to $11.2 million in 2025, then fell by 1.0% to $11.1 million in 2026.
- The last three Non-Current Assets figures came in at $11.1 million (Q1 2026), $11.2 million (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 11.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.06 Mn |
| Dec 31, 2025 | 11.17 Mn |
| Sep 30, 2025 | 11.25 Mn |
| Jun 30, 2025 | 11.40 Mn |
| Mar 31, 2025 | 11.58 Mn |
| Dec 31, 2024 | 11.84 Mn |
| Sep 30, 2024 | 12.31 Mn |
| Jun 30, 2024 | 12.41 Mn |
| Mar 31, 2024 | 12.52 Mn |
| Dec 31, 2023 | 12.60 Mn |
| Sep 30, 2023 | 16.61 Mn |
| Jun 30, 2023 | 16.72 Mn |
| Mar 31, 2023 | 16.98 Mn |
| Dec 31, 2022 | 16.95 Mn |
| Sep 30, 2022 | 17.10 Mn |
| Jun 30, 2022 | 17.20 Mn |
| Mar 31, 2022 | 18.24 Mn |
| Dec 31, 2021 | 18.37 Mn |
| Sep 30, 2021 | 18.35 Mn |
| Jun 30, 2021 | 16.72 Mn |
| Mar 31, 2021 | 17.25 Mn |
| Dec 31, 2020 | 17.75 Mn |
| Sep 30, 2020 | 18.15 Mn |
| Jun 30, 2020 | 18.96 Mn |
| Mar 31, 2020 | 18.63 Mn |
| Dec 31, 2019 | 18.38 Mn |
| Sep 30, 2019 | 44.60 Mn |
| Jun 30, 2019 | 45.72 Mn |
| Mar 31, 2019 | 48.13 Mn |
| Dec 31, 2018 | 48.32 Mn |
| Sep 30, 2018 | 49.14 Mn |
| Jun 30, 2018 | 50.31 Mn |
| Mar 31, 2018 | 51.97 Mn |
| Dec 31, 2017 | 32.13 Mn |
| Sep 30, 2017 | 97,030.00 |
| Jun 30, 2017 | 96,196.00 |
| Mar 31, 2017 | 102,048.00 |
| Dec 31, 2016 | 106,071.00 |
| Sep 30, 2016 | 90,394.00 |
| Jun 30, 2016 | 40,957.00 |
| Mar 31, 2016 | 37,327.00 |
| Dec 31, 2015 | 35,216.00 |
| Sep 30, 2015 | 2.04 Mn |
| Dec 31, 2014 | 155,905.00 |